DusanStefoskiMD

PubMed

• 115 citations
  Freedom from disease activity in multiple sclerosis
  Eva Havrdova, Steven Galetta, Dusan Stefoski, Giancarlo Comi
  Neurology. 2010-04-27
• 136 citations
  Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.
  Floyd A. Davis, Dusan Stefoski, Jean Rush
  Annals of Neurology. 1990-02-01
• 29 citations
  Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica
  Zhihua Ren, Yan Wang, Tao Duan, Jilpa Patel, Thomas Liggett
  Journal of Immunology. 2012-11-01

Journal Articles

• Concerning the application of plasmapheresis in multiple sclerosis.  
  Schauf CL, Stefoski D, Davis FA, McLeod BC, Plasmatherapy
• Linomide in relapsing and secondary progressive MS - Trial design and clinical results.  
  Noseworthy JH, Wolinsky JS, Lublin FD et al, Neurology
• Linomide in relapsing and secondary progressive MS: MRI results.  
  Wolinsky JS, Narayana PA, Noseworthy JH et al and North American Investigators (Stefoski D int al), Neurology
• Intramuscular interferon beta 1-a therapy initiated during a first demyelinating event in multiple sclerosis.  
  Jacobs LD, Beck RW, Simon JH et al and the CHAMPS Study Group (Stefoski D int al), N Engl J Med
• Interferon beta 1-a for optic neuritis patients at high risk for multiple sclerosis.  
  Stefoski D, Am J Ophthalmol
• Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analysis.  
  Beck RW et al (Stefoski D int al), Ann Neurol
• Predictors of short-term disease activity following a first demyelinating event: Analysis if the CHAMPS placebo group.  
  CHAMPS Study Group (Stefoski D int al), Multiple Sclerosis
• MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group.  
  CHAMPS Study Group (Stefoski D int al), Neurology
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl  
  Rudick RA et al (Stefoski D int al), N Engl J Med
• The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL.  
  Calabresi PA, Giovannoni G, Confavreux C et al (Stefoski D int al), Neurology
• A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.  
  Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group (Stefoski D int..., N Engl J Med
• Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.  
  Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock..., J Neurol Sci
• Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and sub...  
  Giovannoni G, Cook S, Rammohan K, et al (Stefoski D int al), Lancet Neurol
• Join now to see all

Books/Book Chapters

• Respiratory dysfunction in neurological diseases. 
  Chapter: Central disturbances of respiration in multiple sclerosis 
  Page 203 - 220Stefoski D, Davis FAEditors: Weiner WJ.Futura NY
• Neurology for Non-Neurologists. 
  Chapter: Multiple sclerosis 
  Page 187 - 196Stefoski DEditors: Weiner WJ, Goetz C.Harper and Row, Philadelphia

Abstracts/Posters

• Composite methylation profiles of blood DNA as biomarkers for multiple sclerosis.
  Melnikov A, Scholtens D, Reder AT, Balabanov R, Stefoski D, Levenson V, Multiple Sclerosis
• White matter integrity in multiple sclerosis and its relationship to cognitive processing speed: A diffusion tensor imaging study.
  Stebbins G, Katsamakis, Carrillo MC, Stefoski D. Bangen KJ Moseley ME, Gabrieli JE, Neurology
• Decreased relapses of multiple sclerosis in patients on 4-aminopyridine.
  Stefoski D, Katsamakis G, Ko M, Mult Scler
• Immunoablation using cyclophosphamide without haematopoietic stem cell rescue for refractory multiple sclerosis.
  Ko M, Katsamakis G, Stefoski D, Shammo J, Gregory S, J Neurol, Meeting of the European Neurological Society, Vienna
• Decreased gray matter density in multiples sclerosis and its relationship to cognitive function.
  Johnson J, Katsamakis G, Stefoski D, Fleischman D, Stebbins G, Organization for Human Brain Mapping Meeting, 11th Annual Meeting, Toronto
• Cost-efficacy analysis of multiple sclerosis therapies: Assessing the impact of neutralizing antibodies.
  Munschauer F, Baker T, Dunn J, Cook R, Likosky W, Stefoski D, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 11th Annual Meeting
• Autologous non-myeloablative hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis.
  Burt RK, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Rose JW, Testori A, Muraro PA, Storek J, Voltarelli J, Multiple Sclerosis
• Natalizumab increases the proportion of disease-free patients in relapsing multiple sclerosis.
  Havrdova E, Bates D, Galetta SL, Giovannoni G, Lublin F, O'Connor P, Phillips JT, Polman C, Stefoski D, Pace A, Hyde R, Kim R, Panzara M, Multiple Sclerosis
• Immunoablation with high-dose cyclophosphamide for refractory multiple sclerosis.
  Tilwalli S, Balabanov R, Stefoski D, Katsamakis G, Ko M, Shammo J, Gregory S, Multiple Sclerosis
• use of biofeedback in the treatment of ataxic dysarthria in patients with multiple sclerosis.
  Maddava K, Wang E, Stefoski D, Katsamakis G, 11th Biennial Conference on Motor Speech Disorders and Speech Motor Control, Williamsburg, VA
• Efficacy of Short Courses of Parenteral Cladribine in Patients with Aggressive Multiple Sclerosis.
  Hartman E, Romero R, Stefoski D, Balabanov R, Javed A, Neurology
• Multiple Sclerosis and Systemic Sarcoidosis: A Double Diagnosis.
  Szewka A, McAndrews M, Ko M, Stefoski D, Balabanov R, Neurology
• Demographic and baseline characteristics associated with freedom from disease activity in natalizumab-treated patients.
  Havrdova E, Galetta SL, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Potts J, Hyde R, ECTRIMS
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Prima...
  Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Riester K, Elkins J, O’Neill G, ECTRIMS
• Novel Interventions With Favorable Resolution Of Natalizumab-Induced Progressive Multifocal Leukoencephalopathy (PML).
  Stefoski D, Ko M, Javed A, Balabanov R, Neurology
• MRI and DTI characteristics of natalizumab associated PML during a novel treatment protocol.
  Javed A, Ko M, Balabanov R, Stefoski D, Neurology
• Immunostimuatory effect of G-CSF may be beneficial in natalizumab-associated PML/IRIS.
  Stefoski D, Balabanov R, Javed A, Brillante R, Ko M, Mult Scler
• Correlation between diffuse EEG abnormalities and cerebral atrophy in senile dementia.
  Stefoski D, Bergen D, Fox J, Morrell F, Huckman M, Ramsey R, Gerontologist
• Intense immune ablative therapy with autologous hematopoetic stem cell rescue for progressive multiple scleorsis : A pilot safety study.
  Cohen BA, Karlin KH, Lobeck L, Russell E, Davis F, Stefoski D, Burns W, Burt R, Neurology
• Adverse effects of intravenous high dose steroid treatments.
  Katsamakis G, Stefoski D, Karlin K, Davis FA, Mult Scler
• Cladribine effective in multiple sclerosis.
  Katsamakis G, Stefoski D, Karlin K, Davis FA, J Neurology
• Opposite changes in IFN-[gamma] and IL-10 mRNA abundance in blood monocytes of multiple sclerosis patients following treatment with intravenous methylprednisolone.
  Quandt FN, Katsamakis G, Stefoski D, Hassen E, Sagett S, Neurology
• T-cell depleted autologous hematopoietic stem cell transplantation for multiple sclerosis.
  Burt RK, Traynor AE, Cohen B, Karlin K, Davis FA, Stefoski D, Terry C, Lobeck L, Rowlings P, Cass T, Burns WH, American Neurological Association 123rd Annual Meeting, Montreal, Canada
• T-cell depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: Report on the first tree patients.
  Burt RK, Traynor AE, Cohen BA, Karlin K, Davis FA, Stefoski D, Terry C, Lobeck L, Russell J, Goolsby C, Rosen S, Gorden LI, Keever-Taylor C, Brush M, Fishman M, Burns WH, ASH 39th Annual Meeting, San Diego, CA
• Autologous lymphocyte depleted hematopoietic stem cell transplantation for rapidly progressive multiple sclerosis; Minimal toxicity from cyclophosphamide/total body ir...
  Burt RK, Traynor AE, Cohen B, Karlin K, Davis FA, Stefoski D, Terry C, Lobeck L, Keever-Taylor C, Burns WH, J Neurol Sci
• Join now to see all

Lectures

• Monoclonal Antibody in the Treatment of Multiple Sclerosis: Natalizumab (Tysabri) and the Evidence Leading to its Approval. 
  Neurology Grand Rounds. Rush University Medical Center, Chicago
• Multiple Sclerosis: From basic complexities to simple solutions. 
  Rush University Medical Center, Chicago
• Compression and Demyelination in Worsening Myelopathic Multiple Sclerosis. 
  Neurology Grand Rounds, Rush University Medical Center, Chicago
• Mobility impairment in multiple sclerosis. 
  Multiple Sclerosis Symposium, Biogen Idec, Lisbon, Portugal
• Immunopathogenetic complexities of multiple sclerosis. 
  Neurology Grand Rounds, SUNY Albany, NY
• Long term safety and efficacy of treatments for multiple sclerosis. 
  47th Argentinean Neurological Congress, Mar del Plata, Argentina
• Various Facets of Natalizumab in the Treatment of Multiple Sclerosis (MS). 
  Elan Pharmaceutical Corporation, Presentation to the Board of Directors, Palo Alto, CA
• Addressing Walking Impairment with Prolonged Release Fampridine. 
  European Neurological Society (ENS), Lisbon, Portugal
• Navigating the Maze of MS Therapy. 
  Neurology Symposium, Melbourne, Australia
• Addressing Mobility in MS. 
  Neurology Symposium, Melbourne, Australia
• Early treatment of MS. 
  Neurology Symposium, Melbourne, Australia
• Moderating walking impairment in multiple sclerosis (MS) – Evolution of conduction modification. 
  Providence Brain and Spine Institute–Providence St. Vincent Medical Center, Portland, OR
• Impact of Dose and Frequency of Interferons-β in the Treatment of Multiple Sclerosis. 
  Scientific Symposium on Multiple Sclerosis. Gedeon Richter, Warsaw, Poland
• Factors Influencing the Long Term Management of Multiple Sclerosis. 
  Neurology Grand Rounds Borgess Medical Center. Kalamazoo, MI
• Multiple Sclerosis: The Disease and Its Management. 
  Southern Illinois University Medical School. Springfield, IL
• Comprehensive Care in Multiple Sclerosis. 
  Neurology Grand Rounds. University of Nebraska, Omaha, NE
• Cladribine in the Treatment of Multiple Sclerosis: Fifteen Years of Experience. 
  5th International Conference on Multiple Sclerosis, Dubrovnik, Croatia
• Un Update on Multiple Sclerosis. 
  Neurology Grand Rounds. Genesis Medical Center, Davenport, IA
• Combination Therapy for Multiple Sclerosis. 
  Multiple Sclerosis Symposium. University of Illinois College of Medicine at Peoria
• The role of Potassium Channel Blockers in the Treatment of Multiple Sclerosis. 
  International Symposium on Multiple Sclerosis. Dubrovnik, Croatia
• Interferons in the Treatment of Multiple Sclerosis. 
  The 25th Danube Neurologic Symposium Ljubljana, Slovenia
• Immunopathogenesis of Multiple Sclerosis. 
  University of Oklahoma Medical Center
• Comprehensive Treatment of Multiple Sclerosis. 
  Grand Rounds. Community Hospital, Munster, IN
• Impacting Physical and Cognitive Disabilities in Multiple Sclerosis. Global QASIMS: The Largest Retrospective Comparative Study in Multiple Sclerosis. 
  Treatment Protocols in Multiple Sclerosis Regional Multiple Sclerosis Forum – Chair. Beirut, Lebanon
• Linking Neutralizing Antibodies to Clinical Outcomes in Multiple Sclerosis. Persistent Efficacy of Intramuscular Interferon Beta 1a in the Treatment of Multiple Sclero... 
  Two Presentations at the Baltic Congress of Neurology. Riga, Latvia
• Join now to see all